Company intelligence / Profile preview

Tenet Medicines

Scotch Plains, New Jersey, United Stateseliemtx.com ↗

Ownership: Public · THC
Development stage: Phase 1

Overview

Tenet Medicines was acquired by Eliem Therapeutics in June 2024. Their lead product candidate, TNT119 (also known as budoprutug), is an anti-CD19 antibody designed to achieve broad and deep depletion of pathogenic B-cells with a favorable tolerability profile. The company was planning to initiate Phase 2 clinical trials for systemic lupus erythematosus and immune thrombocytopenia in the second half of 2024[3][5].

Therapeutic areas: HematologyImmunologyNephrology
Modalities: Monoclonal antibody
Industry: Biotech

Drug pipeline

5 assets

budoprutug

4 more assets in the full pipeline.

Request access →

Financials

Market cap: $21.7B
Total revenue: $5.6B
Enterprise value: $32.7B

Beyond the preview

Go deeper on Tenet Medicines.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tenet Medicines.

Explore the full profile